Motif Bio confident about partner interest in Iclaprim

Graham Lumsden, chief executive of Motif Bio (LON:MTFB), tells Proactive Investors he is confident about the path forward for Iclaprim. After a ‘collaborative meeting’ with the FDA, the American regulator gave the biopharmaceutical company the green light to begin phase 111 clinical trials on its next-generation antibiotic. Lumsden is now putting together a strategic business development plan looking at appropriate partners for one or both of the clinical trials to bring in upfront payments and satisfy funding requirements for the trials. @MasterMetals MasterMetals Blog

from MasterMetals


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s